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Choosing between a less and a more cardioselective 
β ‑blocker (carvedilol/nebivolol versus bisoprolol) in 
the treatment of heart failure: what to choose when? 
In patients with heart failure with impaired con‑
tractile function, all β ‑blockers allowed by guide‑
lines may be used. In addition to the drugs listed 
in the title, metoprolol may also be used. These 
drugs can be used even in patients with asth‑
ma or chronic obstructive pulmonary disease. In 
this group of patients, starting from low doses of 
a β ‑blocker and titration up to optimal or maxi‑
mum tolerated doses is recommended. Reduced 
mortality and exacerbations of these chronic re‑
spiratory diseases were shown in patients treat‑
ed with β ‑blockers.
However, β ‑blockers show some differences, 
including in their electrophysiological effects, 
which makes metoprolol and bisoprolol more ef‑
fective than carvedilol and nebivolol in patients 
with arrhytmias.
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Is it reasonable to use a low maintenance dose of 
a β ‑blocker (eg, carvedilol, 6.25 mg/d) in a patient 
with heart failure in whom the dose cannot be in‑
creased because of bradycardia or atrioventricular 
block? What should be the target dose? Based on 
the results of clinical trials, so called optimal dos‑
es of β ‑blockers, associated with optimal effects 
on mortality and exacerbation rates, were de‑
fined. The doses are as follows: for metoprolol, 
20–200 mg/d; for carvedilol, 50–100 mg/d; for 
nebivolol, 10 mg/d; and for bisoprolol, 10 mg/d.
In patients treated with suboptimal doses of 
β ‑blockers, beneficial effects were also seen but 
they were markedly lower compared with the op‑
timal doses. Therefore, it is reasonable to use even 
low doses of β ‑blockers.
Is the use of combination therapy with furosemide 
and torasemide justified in patients with heart failure? 
Which diuretics can be combined to achieve a higher 
diuretic effect? Is this a reasonable option in patients 
with edema? In the treatment of resistant ede‑
ma, 2 loop diuretics may be used in combination. 
The recommendation on the combination treat‑
ment using different loop diuretics despite their 
synergic effect is a result of the observed differ‑
ences in bioavailability of these drugs, a longer 
duration of effect of torasemide compared with 
furosemide, and additional aldosterone ‑lowering 
properties of torasemide.
In patients with high blood pressure and flu‑
id retention, diuretics from different classes may 
also be combined, for example, a loop diuretic plus 
a thiazide diuretic plus an aldosterone antago‑
nist. Such therapy uses different mechanisms to 
increase the diuretic effect.
In patients with renal failure with glomeru‑
lar filtration rates of 35 ml/min/1.73 m² or less, 
the efficacy of thiazide diuretics and aldosterone 
antagonists is low, and these drugs are therefore 
not recommended.
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Is immunization against influenza and pneumococcal 
infections recommended in patients with heart failure? 
Patients with heart failure should be vaccinated 
to reduce incidence of influenza and pneumo‑
coccal disease and/or to alleviate the infections. 
Infection can dramatically worsen the course of 
heart failure and may lead to death and hospi‑
tal admissions.
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drugs. Therefore, I suggest reducing the dose of 
metoprolol to 25 mg/d and start a loop diuretic. 
Furthermore, when the sinus rhythm is 75 bpm or 
higher, it is necessary to add ivabradine in a dose 
sufficient to achieve a heart rate of 50 to 65 bpm. 
Another alternative for the patient with persis‑
tent heart rate of 75 bpm or higher (sinus rhythm 
or atrial fibrillation) is addition of a digitalis gly‑
coside, which has inotropic effects and will make 
it possible to treat hypertension.
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How to plan potassium supplementation (what formu‑
lation and dose should be used) in a patient treated 
with a diuretic with a tendency to cause hypokalemia? 
Potassium chloride as an extended ‑release for‑
mulation (1 tablet contains 391 mg of potassi‑
um), 2 tablets per day is usually sufficient. In pa‑
tients with persistent potassium levels of less 
than 4 mmol/l, I suggest adding an aldoste‑
rone antagonist (eg, spironolactone, 50 mg/d, 
or eplerenone, 50 mg/d). Reducing the levels of 
aldosterone additionally decreases renal potas‑
sium excretion. However, after approximately 
1 week of such therapy, serum potassium levels 
should be measured.
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A patient with severe edema of the lower extremities, 
ascites, tachycardia, low blood pressure, and previ‑
ously detected markedly reduced ejection fraction re‑
fuses hospitalization. Which drugs are the safest to 
start outpatient treatment? The most important 
thing is patience and repeated offer of hospital ad‑
mission. In 95% of cases, professional, calm, and 
clear argumentation results in the patient’s con‑
sent to hospitalization. However, if the patient 
does not give such consent, I suggest obtaining 
(in a reassuring and clear manner) a written (by 
a patient or by his or her guardian) refusal to ad‑
mission. If this is not possible, an annotation of 
refusal in the presence of a witness (eg, a nurse) 
is sufficient. Such situation is not included in 
the European Society of Cardiology (ESC) guide‑
lines, but logically we have to reduce a number 
of hypotensive drugs in the treatment of heart 
failure. In such circumstances, I suggest starting 
treatment with:
1 a digitalis glycoside (an inotropic drug to im‑
prove myocardial contractility) combined with 
a loop diuretic and a low ‑dose aldosterone antag‑
onist (eg, spironolactone, 25 mg/d, or eplerenone, 
25 mg/d);
2 ivabradine (only in patients with sinus rhythm 
of 75 bpm or higher) combined with a loop diuret‑
ic and a low ‑dose aldosterone antagonist (eg, spi‑
ronolactone, 25 mg/d, or eplerenone, 25 mg/d).
In patients with persistent heart rate of 75 bpm 
or higher despite the therapy with a digitalis gly‑
coside or ivabradine in doses recommended by 
the guidelines, I suggest using a combination ther‑
apy with ivabradine and digoxin, and add a loop 
diuretic and a low ‑dose aldosterone antagonist.
In patients with contraindications to β ‑block‑
ers, the ESC guidelines recommend the use of di‑
goxin and ivabradine in the treatment of heart 
failure. Such patients require follow ‑up visits even 
once a week. When systolic blood pressure ex‑
ceeds 100 mmHg (this effect is usually achieved 
after using at least 2 weeks of the treatment de‑
scribed above), adding a low ‑dose angiotensin‑
‑converting enzyme inhibitor under blood pres‑
sure monitoring should be considered.
In the case of a lack of therapeutic effect, I sug‑
gest a repeated offer of hospital admission.
What treatment should be offered to a female pa‑
tient with heart failure (using metoprolol succi‑
nate, 50 mg/d, as monotherapy), blood pressure of 
100/70 mmHg, and severe edema of the lower extrem‑
ities? This question is in part similar to the pre‑
vious question. Because of low blood pressure, we 
have to minimize the number of antihypertensive 
